# GFI1

## Overview
GFI1 (growth factor independent 1) is a gene that encodes a zinc finger transcriptional repressor protein, which plays a pivotal role in the regulation of hematopoiesis and immune system development. The GFI1 protein is characterized by its zinc finger domains and a SNAG domain, which are essential for its function as a transcriptional repressor. It is involved in maintaining the quiescence and self-renewal of hematopoietic stem cells, as well as regulating the differentiation of myeloid and lymphoid cells. GFI1 exerts its effects by recruiting histone-modifying enzymes to target genes, thereby modulating gene expression and impacting processes such as DNA repair and apoptosis. Clinically, mutations and altered expression of GFI1 are linked to various hematological disorders, including acute myeloid leukemia and severe congenital neutropenia, highlighting its significance in both normal physiology and disease states (Hönes2017Enforced; Person2003Mutations; Möröy2019Role).

## Structure
The GFI1 protein is a transcriptional repressor characterized by its zinc finger domains and SNAG domain. It contains six C2H2-type zinc finger motifs located at the C-terminal region, which are crucial for its DNA-binding capability. Specifically, zinc fingers 3, 4, and 5 are essential for binding to a specific DNA sequence motif, while zinc fingers 1, 2, and 6 facilitate interactions with other proteins (Möröy2019Role; ZweidlerMckay1996Gfi1). The N-terminal SNAG domain, consisting of 20 amino acids, is shared with other transcription factors like SNAIL and SLUG and is involved in transcriptional repression (Möröy2019Role).

The protein's structure includes an intermediate domain that separates the SNAG and zinc finger domains, although this region is not well-conserved across species (Möröy2019Role). GFI1 is subject to post-translational modifications, such as phosphorylation, which influence its activity and stability (Dahl2007The). The protein does not exhibit evidence of dimerization, and its DNA-binding sites do not have a consistent pattern of spacing or orientation (ZweidlerMckay1996Gfi1). There is no detailed information available on the primary, secondary, tertiary, or quaternary structures of GFI1 in the provided context.

## Function
The GFI1 gene encodes a zinc finger transcriptional repressor that plays a crucial role in hematopoiesis, the process of forming blood cellular components. In healthy human cells, GFI1 is involved in the regulation of hematopoietic stem cells (HSCs) and the differentiation of myeloid and lymphoid cells. It helps maintain the quiescence and self-renewal of HSCs, which is essential for preserving their 'stemness' and preventing premature differentiation (Hönes2017Enforced; Hönes2016GFI1). GFI1 functions as a transcriptional repressor by recruiting histone-modifying enzymes to its target genes, leading to gene silencing. This regulation affects myeloid development, macrophage activation, and T and B-lymphocyte differentiation (Möröy2019Role).

GFI1 also plays a significant role in DNA repair and the regulation of TP53, a crucial protein for maintaining genomic stability. It forms a complex with PRMT1 and DNA repair proteins, facilitating their methylation and activation for efficient DNA repair. GFI1 interacts with the tumor suppressor protein p53, recruiting LSD1 to demethylate p53, thereby controlling its activity and preventing over-activation of p53 target genes (Möröy2019Role). GFI1's activity is primarily nuclear, where it binds to DNA and modulates gene expression, impacting immune system development and function (Marteijn2006Diminished).

## Clinical Significance
Mutations and altered expression of the GFI1 gene are associated with several hematological disorders. In acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), reduced GFI1 expression is linked to poor prognosis and accelerated disease progression. This reduction is associated with a block in myeloid differentiation and an increase in granulocyte-macrophage progenitors, which can lead to the formation of leukemia stem cells (Hönes2016GFI1; Möröy2019Role). 

Mutations in GFI1, particularly in its zinc finger domains, can disrupt regulatory networks, contributing to the development of AML. These mutations can also lead to severe congenital neutropenia (SCN) and nonimmune chronic idiopathic neutropenia of adults (NI-CINA), characterized by low neutrophil counts and increased susceptibility to infections (Person2003Mutations). 

The GFI1-36N single nucleotide polymorphism is associated with an increased prevalence of MDS and AML, as well as multiple myeloma, where it correlates with shorter overall survival (Khandanpour2021Prevalence). Reduced GFI1 expression can also lead to a fatal myeloproliferative disease in mice, which can progress to leukemia with additional mutations (Fraszczak2018Reduced).

## Interactions
GFI1 is a transcriptional repressor that interacts with various proteins and nucleic acids to regulate gene expression. It physically interacts with the transcription factor PU.1, inhibiting its activity through direct protein-protein interaction. This interaction is crucial for blocking PU.1-induced macrophage differentiation and promoting granulocyte differentiation (Dahl2007The). GFI1 also interacts with ETS1, where both proteins cooperatively repress the Bax gene expression, a process important in apoptosis regulation (Nakazawa2007Cooperative).

GFI1 is involved in DNA repair by interacting with proteins such as MRE11 and PRMT1, which are part of the DNA damage response pathway. These interactions facilitate the methylation of MRE11 and 53BP1, essential for their roles in DNA repair (Vadnais2018GFI1). GFI1 also interacts with histone deacetylases (HDACs) and CoREST, contributing to its role in transcriptional repression by modifying chromatin structure (D’Souza2011Gfi1).

Additionally, GFI1 interacts with PRDM5, a tumor suppressor, where both can function as transcriptional repressors or activators depending on the context. This interaction involves the zinc finger domains of both proteins and suggests a mechanism where they may prevent each other from interacting with repressive enzymes (Duan2007Epigenetic).


## References


[1. (Hönes2017Enforced) Judith M. Hönes, Aniththa Thivakaran, Lacramioara Botezatu, Pradeep Patnana, Symone Vitoriano da Conceição Castro, Yahya S. Al-Matary, Judith Schütte, Karen B. I. Fischer, Lothar Vassen, André Görgens, Ulrich Dührsen, Bernd Giebel, and Cyrus Khandanpour. Enforced gfi1 expression impedes human and murine leukemic cell growth. Scientific Reports, November 2017. URL: http://dx.doi.org/10.1038/s41598-017-15866-9, doi:10.1038/s41598-017-15866-9. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-017-15866-9)

[2. (Person2003Mutations) Richard E Person, Feng-Qian Li, Zhijun Duan, Kathleen F Benson, Jeremy Wechsler, Helen A Papadaki, George Eliopoulos, Christina Kaufman, Salvatore J Bertolone, Betty Nakamoto, Thalia Papayannopoulou, H Leighton Grimes, and Marshall Horwitz. Mutations in proto-oncogene gfi1 cause human neutropenia and target ela2. Nature Genetics, 34(3):308–312, June 2003. URL: http://dx.doi.org/10.1038/ng1170, doi:10.1038/ng1170. This article has 312 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ng1170)

[3. (Khandanpour2021Prevalence) Cyrus Khandanpour, Christine Eisfeld, Subbaiah Chary Nimmagadda, Marc S. Raab, Niels Weinhold, Anja Seckinger, Dirk Hose, Anna Jauch, Asta Försti, Kari Hemminki, Thomas Hielscher, Manuela Hummel, Georg Lenz, Hartmut Goldschmidt, and Stefanie Huhn. Prevalence of the gfi1-36n snp in multiple myeloma patients and its impact on the prognosis. Frontiers in Oncology, October 2021. URL: http://dx.doi.org/10.3389/fonc.2021.757664, doi:10.3389/fonc.2021.757664. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.757664)

[4. (Fraszczak2018Reduced) Jennifer Fraszczak, Charles Vadnais, Marissa Rashkovan, Julie Ross, Hugues Beauchemin, Riyan Chen, Damien Grapton, Cyrus Khandanpour, and Tarik Möröy. Reduced expression but not deficiency of gfi1 causes a fatal myeloproliferative disease in mice. Leukemia, 33(1):110–121, June 2018. URL: http://dx.doi.org/10.1038/s41375-018-0166-1, doi:10.1038/s41375-018-0166-1. This article has 16 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41375-018-0166-1)

[5. (Vadnais2018GFI1) Charles Vadnais, Riyan Chen, Jennifer Fraszczak, Zhenbao Yu, Jonathan Boulais, Jordan Pinder, Daria Frank, Cyrus Khandanpour, Josée Hébert, Graham Dellaire, Jean-François Côté, Stéphane Richard, Alexandre Orthwein, Elliot Drobetsky, and Tarik Möröy. Gfi1 facilitates efficient dna repair by regulating prmt1 dependent methylation of mre11 and 53bp1. Nature Communications, April 2018. URL: http://dx.doi.org/10.1038/s41467-018-03817-5, doi:10.1038/s41467-018-03817-5. This article has 45 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-018-03817-5)

[6. (Hönes2016GFI1) J M Hönes, L Botezatu, A Helness, C Vadnais, L Vassen, F Robert, S M Hergenhan, A Thivakaran, J Schütte, Y S Al-Matary, R F Lams, J Fraszscak, H Makishima, T Radivoyevitch, B Przychodzen, S V da Conceição Castro, A Görgens, B Giebel, L Klein-Hitpass, K Lennartz, M Heuser, C Thiede, G Ehninger, U Dührsen, J P Maciejewski, T Möröy, and C Khandanpour. Gfi1 as a novel prognostic and therapeutic factor for aml/mds. Leukemia, 30(6):1237–1245, February 2016. URL: http://dx.doi.org/10.1038/leu.2016.11, doi:10.1038/leu.2016.11. This article has 35 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/leu.2016.11)

[7. (Dahl2007The) Richard Dahl, Sangeeta R. Iyer, Kristin S. Owens, Dorothy D. Cuylear, and M. Celeste Simon. The transcriptional repressor gfi-1 antagonizes pu.1 activity through protein-protein interaction. Journal of Biological Chemistry, 282(9):6473–6483, March 2007. URL: http://dx.doi.org/10.1074/jbc.M607613200, doi:10.1074/jbc.m607613200. This article has 121 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M607613200)

[8. (Marteijn2006Diminished) Jurgen A. F. Marteijn, Laurens T. van der Meer, Liesbeth Van Emst, Theo de Witte, Joop H. Jansen, and Bert A. van der Reijden. Diminished proteasomal degradation results in accumulation of gfi1 protein in monocytes. Blood, 109(1):100–108, August 2006. URL: http://dx.doi.org/10.1182/blood-2006-02-003590, doi:10.1182/blood-2006-02-003590. This article has 20 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2006-02-003590)

[9. (D’Souza2011Gfi1) Sonia D’Souza, Davide del Prete, Shunqian Jin, Quanhong Sun, Alissa J. Huston, Flavia Esteve Kostov, Benedicte Sammut, Chang-Sook Hong, Judith L. Anderson, Kenneth D. Patrene, Shibing Yu, Chinavenmeni S. Velu, Guozhi Xiao, H. Leighton Grimes, G. David Roodman, and Deborah L. Galson. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood, 118(26):6871–6880, December 2011. URL: http://dx.doi.org/10.1182/blood-2011-04-346775, doi:10.1182/blood-2011-04-346775. This article has 84 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2011-04-346775)

[10. (Duan2007Epigenetic) Zhijun Duan, Richard E. Person, Hu-Hui Lee, Shi Huang, Jean Donadieu, Raffaele Badolato, H. Leighton Grimes, Thalia Papayannopoulou, and Marshall S. Horwitz. Epigenetic regulation of protein-coding and microrna genes by the gfi1-interacting tumor suppressor prdm5. Molecular and Cellular Biology, 27(19):6889–6902, October 2007. URL: http://dx.doi.org/10.1128/MCB.00762-07, doi:10.1128/mcb.00762-07. This article has 113 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.00762-07)

[11. (Nakazawa2007Cooperative) Y Nakazawa, M Suzuki, N Manabe, T Yamada, F Kihara-Negishi, T Sakurai, D G Tenen, A Iwama, M Mochizuki, and T Oikawa. Cooperative interaction between ets1 and gfi1 transcription factors in the repression of bax gene expression. Oncogene, 26(24):3541–3550, January 2007. URL: http://dx.doi.org/10.1038/sj.onc.1210140, doi:10.1038/sj.onc.1210140. This article has 30 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1210140)

[12. (Möröy2019Role) Tarik Möröy and Cyrus Khandanpour. Role of gfi1 in epigenetic regulation of mds and aml pathogenesis: mechanisms and therapeutic implications. Frontiers in Oncology, August 2019. URL: http://dx.doi.org/10.3389/fonc.2019.00824, doi:10.3389/fonc.2019.00824. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2019.00824)

[13. (ZweidlerMckay1996Gfi1) Patrick A. Zweidler-Mckay, H. Leighton Grimes, Marcella M. Flubacher, and Philip N. Tsichlis. Gfi-1 encodes a nuclear zinc finger protein that binds dna and functions as a transcriptional repressor. Molecular and Cellular Biology, 16(8):4024–4034, August 1996. URL: http://dx.doi.org/10.1128/mcb.16.8.4024, doi:10.1128/mcb.16.8.4024. This article has 237 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.16.8.4024)